Results 41 to 50 of about 149 (146)

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Bioengineering facets of the tumor microenvironment in 3D tumor models: insights into cellular, biophysical and biochemical interactions

FEBS Open Bio, EarlyView.
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik, Deniz Bakkalci, Alexander J. MacRobert, Umber Cheema   +3 more
wiley   +1 more source

Adenosine A3 receptor antagonists as anti‐tumor treatment in human prostate cancer: an in vitro study

FEBS Open Bio, EarlyView.
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli, Andrea Spinaci, Cui Chang, Rosaria Volpini, Catia Lambertucci, Matteo Landriscina, Vincenza Conteduca, Consuelo Amantini, Cristina Aguzzi, Laura Zeppa, Martina Giangrossi, Laura Soverchia, Matteo Santoni, Massimo Nabissi, Giorgio Santoni, Carlo Polidori   +15 more
wiley   +1 more source

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

FEBS Open Bio, EarlyView.
Carbonic anhydrase IX (CAIX) is a well‐recognised therapeutic target and prognostic biomarker in cancer. We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive ...
Zane Kalniņa, Ilva Liekniņa, Svetlana Koteloviča, Ramona Petrovska, Gediminas Žvinys, Agne Petrosiute, Asta Zubrienė, Matīss Toms Laugalis, Vendija Skeltona, Juris Jansons, Madara Kreishmane, Edita Čapkauskaitė, Daumantas Matulis, Kaspars Tārs   +13 more
wiley   +1 more source

Lung volumes. [PDF]

British Journal of Clinical Pharmacology, 1979
openaire   +2 more sources

Evaluating the use of diagnostic CT with flattening filter free beams for palliative radiotherapy: Dosimetric impact of scanner calibration variability

Journal of Applied Clinical Medical Physics, Volume 26, Issue 6, June 2025.
Abstract Purpose Palliative radiotherapy comprises a significant portion of the radiation treatment workload. Volumetric‐modulated arc therapy (VMAT) improves dose conformity and, in conjunction with flattening filter free (FFF) delivery, can decrease treatment times, both of which are desirable in a population with a high probability of retreatment ...
Madeleine L. Van de Kleut, Lesley A. Buckley, Elsayed S. M. Ali   +2 more
wiley   +1 more source

Commissioning of Halcyon enhanced leaf model in the Eclipse treatment planning system: Focus on simple slit fields and VMAT dose calculation

Journal of Applied Clinical Medical Physics, Volume 26, Issue 6, June 2025.
Abstract Purpose The dual‐layer multileaf collimator (MLC) in Halcyon adds complexities to the dose calculation process owing to the variability of dosimetric characteristics with leaf motion. Recently, an enhanced leaf model (ELM) was developed to refine the MLC model in the Eclipse treatment planning system. This study investigates the performance of
Ryohei Miyasaka, Mari Shirai, Mitsunobu Igari, Yume Kojima, Yuki Kozawa, Toru Kawachi, Ryusuke Hara   +6 more
wiley   +1 more source

Stereotactic radiotherapy for metastatic brain tumors: A comparative analysis of dose distributions among VMAT, Helical TomoTherapy, CyberKnife, Gamma Knife, and ZAP‐X

Journal of Applied Clinical Medical Physics, Volume 26, Issue 6, June 2025.
Abstract This study evaluates various radiotherapy techniques for treating metastatic brain tumor (BT), focusing on non‐coplanar volumetric modulated arc radiotherapy (NC‐VMAT), coplanar VMAT (C‐VMAT), Helical TomoTherapy (HT), CyberKnife (CK), Gamma Knife (GK), and ZAP‐X.
Toshihiro Suzuki, Masahide Saito, Ryutaro Nomura, Hikaru Nemoto, Naoto Yanagisawa, Ryuma Sawada, Zennosuke Mochizuki, Naoki Sano, Hiroshi Onishi, Hiroshi Takahashi   +9 more
wiley   +1 more source

The Volume of Blood in the Lungs [PDF]

Circulation, 1966
openaire   +3 more sources